Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

TG Therapeutics gets DSMB approval to continue two oncology trials

UNITY-CLL trial involves treatment naïve, relapsed or refractory chronic lymphocytic leukaemia (CLL) patients. Credit: Nephron.



  • TG Therapeutics gets DSMB nod to continue two oncology trials

Go Top